Abstract
Sunitinib is a multispecific kinase inhibitor and one of its targets is the kinase GRK5, which is regulating a multitude of G protein-coupled receptors (GPCRs). In this study we demonstrate that a decreased GRK5 expression induced by knock-down experiments or sunitinib treatment hampers the migration of cancer cell lines. A proteomic analysis revealed many pathways related to cell migration which were down regulated upon the GRK5 knock-down. Furthermore, we found in MDA-MB-231 breast cancer cells that the inhibition of migration is mediated by the GPCR gastrin releasing peptide receptor (GRPR) leading to a reduced expression of migration regulating downstream targets like CDC42 and ROCK1. An in silico Kaplan Meier analysis revealed that GRK5 and GRPR overexpression reduces the distant metastasis free survival in triple-negative breast cancer (TNBC) patients. Thus, we suggest a novel anti-migratory effect of impaired GRK5 expression which induces a negative feedback loop on GRPR signalling.
Similar content being viewed by others
Introduction
G protein-coupled receptors (GPCRs) are the largest group of cell surface receptors in humans and comprise of more than 800 members1. They are also known as seven-transmembrane receptors and are involved in many physiological processes like neurotransmission, metabolism, immune response, regulation of blood pressure and cardiac activity2. Therefore, a tight regulation of these signalling cascades is of great importance to avoid disease formation. One regulatory protein class are the AGC kinases to which the G protein-coupled receptor kinase (GRK) family belongs. These seven serine-threonine kinases can be categorized according to their structural properties into three subgroups: the visual subfamily (GRK1, GRK7), the GRK2 subfamily (GRK2, GRK3) and the GRK4 subfamily (GRK4, GRK5, and GRK6)3,4. In general, all GRKs regulate the GPCR signalling by phosphorylating agonist-activated GPCRs in the third cytoplasmic loop and/or the C-terminal tail. This leads to the recruitment of β-arrestins and subsequently to the uncoupling of the G proteins. This process is termed GPCR desensitization5,6. β-arrestins are also known to function as scaffold proteins that facilitate the internalization of GPCRs thus resulting in the recycling or lysosomal degradation of the receptor7.
Due to the fact that the seven GRKs regulate more than 800 GPCRs it is obvious that GRKs affect the signal transduction of complex signalling cascades which comprise of more than one GPCR. Therefore, aberrant expression of these kinases leads to malfunction of several GPCRs and consequently to diseases like diabetes, hypertension, cardiac dysfunction, Alzheimer’s disease and cancer1,5. Tumorigenesis was shown to be influenced mainly by GRK2 and GRK58,9,10. These kinases often function as oncogenes in glioblastoma11, prostate9,12, pancreas13, non-small-cell lung14 and breast cancer15. According to the Human Protein Atlas, 50% of the analysed breast cancer patients possessed elevated GRK2 or GRK5 expression16,17, whereas the latter was shown to result in even worse prognosis concerning the 5-years survival rate. Nevertheless, the role of GRK5 in breast cancer has not been studied and the mechanism of action remains rather unclear. Breast cancer affects one of eight women during their lifetime and is estimated to be the second leading cause of cancer deaths in women in the United States in 201818. Therefore, it is of great importance to identify novel predictive biomarkers and druggable targets associated with this disease.
Therefore, the aim of this study was to elucidate the function of GRK5 in breast cancer and investigate whether the targeting of GRK5 could have a beneficial effect on cancer treatment. Sunitinib is the most potent, approved small-molecule inhibitor (SMI) targeting GRK519,20. Since 2006 sunitinib is approved by the FDA for the treatment of gastrointestinal stromal tumours, which are refractory or intolerant to imatinib treatment, and for advanced, metastatic renal cell carcinoma (mRCC)21,22. This multispecific kinase inhibitor was shown to mainly inhibit the receptor tyrosine kinases (RTKs) vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR)23 thereby blocking the angiogenesis of tumours. Thus, we additionally investigated the effect of sunitinib on GRK5 and breast cancer cells in vitro.
Results
Analysis of different breast cancer cell lines reveals increased GRK5 expression in mesenchymal cells
To evaluate the expression level of GRK5 in breast cancer, a qPCR analysis was performed. The cell lines were grouped according to their morphology. Spindle-like cell lines were regarded as mesenchymal (MDA-MB-415, BT-549, MDA-MB-435s, HS-578T, MDA-MB-231) and cobblestone-like growing cells were considered as epithelial cells (MCF-7, BT-474, ZR-75, SKBR-3, MDA-MB-361). We observed that GRK5 is significantly higher expressed in mesenchymal-like breast cancer cells and that MDA-MB-231 cells, a metastatic, triple-negative breast cancer cell line, showed the highest GRK5 expression level of all analysed cell lines (Fig. 1A). A similar expression pattern was observed by western blot analysis in an additional panel of cancer cell lines (Supplementary Fig. S1). Therefore, MDA-MB-231 was chosen as model for further experiments.
The expression levels of the other GRK4-family members, GRK4 and GRK6, were analysed in MDA-MB-231 cells. Here, GRK6 is as highly expressed as GRK5, whereas GRK4 shows a very low expression level (Fig. 1B).
Characterization of an inducible shGRK5 knockdown in MDA-MB-231 elucidates the impact of GRK5 on cell viability, apoptosis, migration and invasion in breast cancer
In order to further investigate the function of GRK5 in triple-negative breast cancer (TNBC), MDA-MB-231 cells stably expressing a doxycycline inducible shGRK5 were generated (termed MDA-MB-231 TRIPZ-shGRK5 in the following). As a gene coding for RFP is localized downstream of the doxycycline (DOX) inducible promotor, a fluorescence signal indicates shGRK5 expression upon DOX induction (Fig. 1C). Subsequently, we investigated the mRNA expression level of GRK5 in MDA-MB-231 TRIPZ-shGRK5 and MDA-MB-231 wild-type (wt) cells 72 h after inducing with DOX to determine the knockdown (KD) efficiency (Fig. 1C).
Moreover, possible compensatory effects of GRK4-family members were investigated in a time-dependent manner after DOX treatment and could be excluded as the mRNA expression levels of GRK4 and GRK6 remain similar after the GRK5 KD (Fig. 1D).
To elucidate the physiological impact of GRK5 KD in TNBC development and progression, cell viability and apoptosis induction were measured 90 h after DOX stimulation in MDA-MB-231 TRIPZ-shGRK5 cells. We observed that the GRK5 KD neither reduces the cell viability nor increases the apoptosis rate (Supplementary Fig. S2).
Proteomic analysis and boyden chamber experiments reveal impact of GRK5 on cancer cell migration
To investigate whether GRK5 influences breast cancer development and progression in general, a proteomics approach utilizing LC-MS was performed. Therefore, MDA-MB-231 TRIPZ-shGRK5 were seeded in quintuples, twice induced with doxycycline and harvested after 90 h (Fig. 2A). The subsequent proteomic analysis revealed 2220 proteins that were identified at least three times in induced and not-induced samples. The following gene set enrichment analysis (GSEA) utilizing Gene Ontology Biological Process (GO_BP) elucidated up and down regulated signalling pathways upon GRK5 KD. By clustering the resulting pathways in signalling cascades important for tumorigenesis it was observed that a decrease in GRK5 expression primarily leads to a down regulation of cell motility pathways (Fig. 2B).
To validate the effect of GRK5 on cancer cell migration, boyden chamber experiments with and without matrigel coating were performed. Thereby, we showed that GRK5 KD significantly hampers both migration and invasion in TNBC cells (Fig. 2C,D). Additionally, a KD by a pool of GRK5 siRNAs was performed in another breast cancer (HS-578T) and two prostate cancer cell lines (DU-145, PC-3) (Fig. 2E) and its effect on cancer cell migration was confirmed (Fig. 2F).
GRK5 KD hampers chemotaxis of MDA-MB-231 cells towards bombesin
To identify the underlying signalling pathways, different chemoattractants were analysed in a boyden chamber experiment with respect to their pro-migratory activity on MDA-MB-231 cells. Moreover, it was investigated whether this effect can be blocked or reduced by a siGRK5 KD. We demonstrate that only bombesin, bradykinin and insulin increased the migratory behaviour of MDA-MB-231 cells, which can be significantly decreased by a GRK5 KD in the case of bradykinin and bombesin (Fig. 3A,B). As bombesin shows the most significant change in migratory behaviour this ligand was analysed further.
The impact of bombesin on the migration of TNBC cells was also examined in MDA-MB-231 TRIPZ-shGRK5 cells to exclude transfection artefacts, as transfection agents could influence cancer cell migration. Here, the chemotactic effect of bombesin was also reduced by shGRK5 (Fig. 3C). Furthermore, the influence of GRK5 and bombesin on the invasiveness of MDA-MB-231 TRIPZ-shGRK5 cells was investigated. As depicted in Fig. 3D, a reduction of GRK5 expression leads to a decreased invasion of TNBC cells towards a bombesin gradient.
Reduction in GRPR expression by GRK5 KD decreases chemotaxis of MDA-MB-231 towards bombesin
The gastrin releasing peptide receptor (GRPR) is the cellular receptor of bombesin and therefore, its expression levels were analysed in different breast cancer cells to confirm its impact on migration. Figure 4A shows that GRPR is significantly higher expressed in mesenchymal-like breast cancer cells. Subsequently, the influence of the GRK5 KD on the GRPR signalling pathway was investigated. Here, we observed that the autocrine activation loop of the GRPR signalling is hampered upon GRK5 KD since the mRNA level of GRPR as well as that of its natural ligand GRP was reduced (Fig. 4B). A GRPR KD on the other hand had no impact on the GRK5 expression (Supplementary Fig. S3). Next, the impact of GRPR on cell migration of TNBC was examined. We detected that GRPR KD reduces the migratory behaviour of MDA-MB-231 to a similar extent as a GRK5 KD (Fig. 4C). In order to determine whether GRPR is the only GPCR that is regulated by GRK5 and thus is responsible for the reduced chemotaxis towards bombesin, cells were transfected with both siGRK5 and siGRPR. As depicted in Fig. 4D this double-KD is not further reducing the migration of MDA-MB-231 cells indicating that GRPR is the main player in the chemotactic process which is regulated by GRK5.
By comparing the measured migration data, we observed a constant reduction in the migratory behaviour of 25–30% upon GRK5 KD, GRPR KD and the double KD of GRK5 and GRPR emphasizing the key role of GRPR in GRK5 mediated migration.
Sunitinib treatment hampers cell migration by reducing the expression of GRK5 and GRPR
Sunitinib is the most potent, approved GRK5 inhibitor19,20. To evaluate the clinical relevance of our findings MDA-MB-231 cells were treated with this SMI and its effect on cell viability, migration, GRK5 and GRPR expression as well as GRPR signalling was investigated. Figure 5A shows that 5 µM sunitinib treatment reduces the cell viability of TNBC cells. Therefore, only lower, non-toxic concentrations were utilized for the cell migration analysis. Here, we demonstrated that 1 µM sunitinib treatment significantly reduces the migration of breast cancer cells. A similar effect was detected for the GRK5 KD. The impact of sunitinib treatment on the expression of GRK4-family members was investigated. Sunitinib significantly reduces the expression only of GRK5 - no significant expression changes were observed for GRK4 and GRK6 (Fig. 5B). Additionally, sunitinib significantly decreases the expression of GRPR and down-stream targets like CDC42 and ROCK1 (Fig. 5C). To investigate whether the GRK5 inhibition, which leads to impaired GRPR signalling and eventually reduced migration, has an impact on patient survival, we analysed patient data in silico. The Kaplan-Meier Plotter24 revealed that GRK5 and GRPR overexpression shows a tendency to reduce the distant metastasis free survival (DMFS) in TNBC patients (Fig. 5D). Therefore, we hypothesize that sunitinib treatment of TNBC prolongs DMFS and thus could improve the patient outcome (Fig. 6).
Discussion
Previous studies have shown that GRK5 affects the migration of prostate cancer via moesin12 and of non-small cell lung cancer cells via vinculin14. However, the function of GRK5 in breast cancer and the involved GPCRs remain unclear. In this study, a breast cancer cell line screen revealed that GRK5 is mainly expressed in TNBC cell lines, which possess a mesenchymal like phenotype and are able to migrate. Accordingly, the GRK5 KD by a pool of siRNAs and the inducible shRNA in MDA-MB-231 cells reduced cell migration and invasion as well as the expression of proteins involved in cell migration pathways. In order to uncover the responsible GPCRs different ligands were used as chemoattractants. Here, bombesin stimulation, amongst others, resulted in significantly increased cell migration which can be blocked by the GRK5 KD, mediated by both, the siRNA and shRNA approach. This finding led to the assumption that GRK5 interferes with the GRPR signalling pathway, as bombesin, an artificial ligand, binds and activates the GRPR25,26,27. GRPR is an important receptor in breast cancer and is overexpressed in up to 96% of breast cancer patients28. An elevated GRPR expression in breast cancer tissue worsens the prognosis16,17. Our expression analysis in different breast cancer cell lines revealed that GRPR is significantly higher expressed in mesenchymal like breast cancer cell lines and correlates with the GRK5 expression. The subsequent qPCR analysis of GRPR and its natural ligand GRP upon GRK5 KD displayed decreased GRPR and GRP expression. Vice versa the KD of GRPR had no influence on the GRK5 expression. Thus, the GRK5 KD hampers the autocrine signalling mechanism by inhibiting the expression of both the endogenous ligand as well as that of the corresponding receptor. GRPR is the sole receptor involved in the chemotaxis of cancer cells towards the ligands GRP/bombesin29,30. The decrease in its expression by GRK5 KD therefore directly impacts the migration of cancer cells. It was previously shown that the increase in GRPR signalling leads to enhanced cancer cell migration and invasion in various cancer types31,32. However, there are many more GPCRs involved in migration like the bradykinin receptor33, angiotensin receptor34, endothelin receptor35 and thrombin receptor36.Our ligand screen however revealed, that only bradykinin and bombesin stimulated migration was hampered by the GRK5 KD and are thus the crucial pathways influenced by GRK5. Moreover, we performed a KD with siRNAs against GRPR and a double KD with siRNAs against GRK5 and GRPR, and investigated the effect on migration. It was shown that all analysed KD experiments with siGRK5, shGRK5, siGRPR and the double KD of GRK5/GRPR, had the same impact on cell migration. We therefore conclude, that the GRPR signalling pathway is an important migratory mechanism which is regulated by GRK5. The knock-down of GRK5 activates a negative feedback loop by attenuating the expression of GRP and GRPR, finally leading to reduced migration in our in vitro system.
To evaluate the clinical significance of our findings, TNBC cells were treated with sunitinib, the most potent, FDA approved GRK5 inhibitor19,20. We observed that sunitinib hampers the migration of MDA-MB-231 cells at non-toxic doses. Previously, it was already shown that sunitinib hampers cell migration in different cancer subtypes but only at toxic doses37,38. Thus, these studies hardly allow a clear discrimination between cytotoxicity and migration. Furthermore, we performed an expression analysis of all GRK4-family members, GRPR and GRPR down-stream signalling components to elucidate whether the effect of sunitinib on cancer cell migration is based on the GRK5-GRPR signalling cascade. As sunitinib is a multispecific kinase inhibitor this SMI inhibits besides GRK5 e.g. VEGFR and PDGFR19,20,38,39. Our results show, that sunitinib treatment not only inhibits GRK5 but also significantly reduces its expression whereas GRK4 and GRK6 expression remains stable. Additionally, we observed that sunitinib treatment reduced the expression of GRPR and down-stream signalling components. As GRPR is no reported target gene of sunitinib, it is likely that sunitinib decreases the expression of GRK5 thus indirectly leading to the downregulation of GRPR and its downstream targets RAC1, CDC42 and ROCK1. The latter three proteins belong to the Rho GTPase family and are crucial players in cell migration40,41. Previous studies have shown that increased CDC42 and ROCK1 expression directly correlates with elevated actomyosin contractility, actin turnover and actin polymerization and eventually facilitate the migration of cancer cells42. Thus, sunitinib treatment of TNBC cells might reduce their ability to migrate by down regulating GRK5 resulting in the decreased expression of GRP, GRPR, CDC42 and ROCK1. Moreover, this finding might mechanistically explain the prolonged survival of mRCC patients upon sunitinib treatment43. Here, this therapy not only reduces the metastatic burden but also avoids the development of new metastases and thus leads to an improved patient outcome.
Taken together, this study shows that GRK5 KD hampers the chemotaxis of MDA-MB-231 cells towards bombesin by down regulating the GRPR. Furthermore, we observed that treatment with the multispecific kinase inhibitor sunitinib decreases the cancer cell migration by reducing the GRK5 expression levels resulting in attenuated GRPR signalling, depicting a novel mechanism of action of a well-known drug. We therefore encourage further studies on this mechanism and speculate, that the implementation of sunitinib in TNBC treatment regimen could be a promising option to reduce the formation of metastases which is still one of the major obstacles in the treatment of TNBC.
Materials and Methods
Reagents
Doxycycline hyclate was purchased from Sigma-Aldrich (St. Louis, Missouri, USA) (cat.nr. D9891). Bombesin acetate salt hydrate (cat.nr. B4272), Bradykinin acetate salt (cat.nr. B3259), human angiotensin II (cat.nr. A9525), endothelin I (cat.nr. E7764), lysophosphatidic acid sodium salt (cat.nr. L7260), human thrombin (cat.nr. T4393), glucose (cat.nr. D7021) and human insulin (cat.nr. I3536) were purchased from Sigma-Aldrich. Sunitinib malate was purchased from Sigma-Aldrich (cat.nr. PZ0012). Lipofectamine 3000 was purchased from ThermoFisher Scientific (Waltham, Massachusetts, USA) (cat.nr. L3000008).
cDNA of different breast cancer cell lines
The cDNA of the different breast cancer cell lines was a kind gift of Axel Ullrich’s lab.
Cell culture
MDA-MB-231 cells were obtained from DSMZ (Braunschweig, Germany) MDA-MB-231 TRIPZ-shGRK5 were generated in our lab and both were cultured in DMEM high glucose supplemented with 10% fetal calf serum (FCS, Gibco) at 37 °C and 5% CO2. HS-578T, DU-145 and PC-3 were obtained from ATCC (Manassas, Virginia, USA) and cultured according to manufacturer’s instructions. All cells were authenticated according to ANSI/ATCC standard ASN-0002 and routinely tested and confirmed as mycoplasm free.
Generation of stable MDA-MB-231 TRIPZ-shGRK5
MDA-MB-231 cells were transduced with the doxycycline-inducible TRIPZ-shGRK5 [Clone-ID: V3THS_312367; Sequence: TCGTGAGCAGCATCTTGCA (Dharmacon)] construct utilizing a 2nd generation lentiviral system generated with the plasmids pCMV-dR8.2 dvpr (Addgene plasmid # 8455) and pCMV-VSV-G (Addgene plasmid # 8454), which were a gift from Bob Weinberg44. After transduction, a 48 h selection with 5 µg/ml puromycin was performed.
Stimulation of the cells with doxycycline was performed in a concentration of 5 µg/ml in DMEM high glucose + 10% FCS for 90 h for mRNA, protein, migration and invasion analysis. Medium was replaced with fresh, doxycycline containing medium every 48 h to compensate for doxycycline degradation.
siRNA transfection
For siRNA transfection 300 000 cells/well were seeded in a 6-well plate and transfected at the same time with 5 µl Lipofectamine 3000 and 12.5 pmol siRNA per well.
siGRK5: SMARTpool: ON-TARGETplus Human GRK5 siRNA (L-004626-02, Dharmacon, Lafayette, Colorado, USA)
scramble control: ON-TARGETplus Non-targeting Pool (D-001810-10, Dharmacon)
siGRPR: Silencer Select siGRPR s6230 (4392420, Thermo Fisher)
RNA-lysis and purification
90 h prior to RNA lysis cells were seeded at a confluence of 50% and either transfected with siRNA or stimulated with doxycycline. Subsequently cells were harvested using RNeasy Mini Kit (Qiagen, Venlo, Netherlands) following the manufacturer’s protocol.
cDNA synthesis
Upon RNA purification 1000 ng RNA were taken to synthesize cDNA according to manufacturer’s protocol using qScript cDNA Synthesis Kit (Quantabio, Beverly. Massachusetts, USA).
Quantitative polymerase chain reaction (qPCR)
To analyse the mRNA expression a qPCR was performed using the LightCycler 480 (Roche, Basel, Switzerland), the Universal Probe Library (UPL, Roche) and LighCycler 480 Probes Master (Roche). The examined mixture contained 10 µl Probes Master, 4.4 µl nuclease free water, 0.2 µl left primer (20 µM), 0.2 µl right primer (20 µM), 0.2 µl probe and 5 µl cDNA per well. The utilized primer probe pairs are listed in the table below.
left primer | right primer | probe | |
GRK5 | aagtccatctgcaagatgctg | ggggtgtctcttgacctctg | # 26 |
GRPR | cccgtggaagggaatataca | gcggtacaggtagatgacatga | # 36 |
GRP | cagccacctcaacccaag | tggagcagagagtctaccaactt | # 61 |
ROCK1 | gatcccaaatcggaagtgaa | caaatcatataccaaagcatccaa | # 42 |
CDC42 | tggagtgttctgcacttacaca | ggctcttcttcggttctgg | # 37 |
RAC1 | ctgatgcaggccatcaagt | caggaaatgcattggttgtg | # 77 |
GAPDH | tccactggcgtcttcacc | ggcagagatgatgaccctttt | # 45 |
For quantification the 2−ΔCt or the 2−ΔΔCt method was applied and GAPDH was used as an internal standard.
Protein lysis and western blot
Cells were lyzed at 80% confluence or 72 h after siRNA transfection with RIPA buffer containing 1% Triton X. 30 μg protein were separated using a SDS-PAGE and subsequently transferred to a nitrocellulose membrane. After one hour blocking with TRIS-buffered saline with Tween20 (TBST) containing 3% nonfat dry milk, the blots were incubated overnight at 4 °C with GRK5-antibody (Millipore, Burlington, Massachusetts, USA, cat.nr. 05-466) solution in TBST containing 3% nonfat dry milk, followed by several washing steps. Afterwards, membranes were incubated for one hour in horseradish peroxidase conjugated anti-mouse (goat anti-mouse-hrp, Sigma Aldrich) secondary antibody at room temperature. After additional washing steps, detection was performed using enhanced chemiluminscence (ECL, GE Healthcare, Chicago, Illinois, USA) on X-ray films (Amersham Hyperfilm ECL, GE Healthcare). The α-Tubulin antibody (Sigma Aldrich, cat.nr. T9026) was used as loading control.
Evaluation of cell viability and apoptosis induction
To determine the impact of doxycycline and the GRK5 KD on cell viability the CellTiter-Glo luminescent cell viability assay (Promega, Madison, Wisconsin, USA) was utilized. To assess the apoptosis induction upon doxycycline treatment and GRK5 KD the Caspase-Glo 3/7 Assay (Promega) was used. 90 h prior to both measurements 3 000 cells/well of MDA-MB-231 TRIPZ-shGRK5 cells were seeded in 96-well plates and treated with the indicated concentrations of doxycycline (N = 3).
Proteomics sample preparation
For proteomics analysis 300 000 cells/well were seeded (N = 5) in a 6-well plate and stimulated every 48 h with 5 µg/ml doxycycline for 90 h. Subsequently, cells were washed three times with cold PBS and lysed with a buffer containing 8 M urea and 400 mM ammonium bicarbonate. Ultrasound was used to support cell lysis and finally the protein samples were purified using QIA-shredder devices (Qiagen). For reduction, 30 µg of total protein was incubated for 30 min at a final concentration of 5 mM dithioerythritol (DTE). Cleaved bisulfide bonds were blocked using iodoacetamide (final concentration 15 mM) for 30 min in the dark. After dilution with water to a concentration of 1 M urea, proteins were first digested for 4 h with 300 ng LysC (FUJIFILM Wako Pure Chemicals, Osaka, Japan) and subsequently digested over night with 600 ng porcine trypsin (Promega, Madison, WI, USA) at 37 °C. Peptides were separated and identified on an Ultimate 3000 (Thermo Scientific, Waltham, MA, USA) nano-chromatography system coupled to a QExavtive HF-X instrument (Thermo Scientific). 2.5 µg of peptides were dissolved in 15 µl solvent A (0.1% formic acid in water) and transferred to a capillary trap column (PepMap 100 C18, 100 µm × 2 cm, 5 µM particles, Thermo Scientific). Separation was performed at 250 nL/min (Column: PepMap RSLC C18, 75 µm × 50 cm, 2 µm particles, Thermo Scientific) with a 160 min gradient from 5% solvent A to 25% solvent B (0.1% formic acid in acetonitrile) and a subsequent 10 min gradient from 25% to 40% solvent B. MS spectra were acquired using a top 15 data dependent CID method. Precursor spectra were acquired at a resolution 60,000 (mass-range: 350–1600) and MS/MS spectra at a resolution of 15,000.
Migration and invasion analysis
For migration and invasion analysis cells were transfected with siRNA or stimulated with 5 µg/ml doxycycline 72 h prior to the experiment. Subsequently, 750 µl DMEM high glucose supplemented with 0.5% FCS and the indicated ligand was added to the lower well of the boyden chamber system Corning BioCoat Matrigel Invasion Chamber (Corning, Corning, New York, USA) in the case of invasion analysis and Falcon Cell Culture Inserts ([8 µm pores] Coring) in the case of migration analysis. The inserts (N = 3) were filled with 500 µl of a cell suspension containing 50 000 cells in DMEM high glucose supplemented with 0.5% FCS. 18 h later the cell suspension was removed and the inserts were put into 500 µl crystal violet solution containing 20% methanol for at least 10 min. Finally, the inserts were washed three times with demineralized water and kept overnight at room temperature. To determine the amount of migrated/invaded cells five microscopic pictures (magnification 10x) of each insert were made (top, bottom, left, right, center) and afterwards analysed using the ImageJ software.
Sunitinib treatment
For cell viability measurement 3 000 MDA-MB-231 cells/well were seeded in triplicates in a 96-well plate and treated with the indicated concentrations for 90 h. Afterwards the CellTiter-Glo luminescent cell viability assay (Promega) was utilized to measure cytotoxicity. To analyse the impact of sunitinib on migration 300 000 cells/well were seeded in a 6-well plate and pre-treated with sunitinib at the indicated concentrations for 72 h. Subsequently, sunitinib was added to the starvation medium (DMEM + 0.5% FCS) for the following boyden chamber experiment. Here, 50 000 cells/well were seeded in triplicates to the insert. For gene expression analysis 300 000 MDA-MB-231 cells/well were seeded in 6-well plates and treated with 1 µM sunitinib for 90 h.
Bioinformatics
Statistical significance was calculated utilizing a two-tailed Student’s t-test for the comparison of two samples and one-way ANOVA with Dunnett’s Multiple Comparison Test or multiple t-tests utilizing two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli,for the comparison of several samples with the control. *p < 0.05, **p < 0.01, ***p < 0.001.
To process the mass spectrometry (MS) data MaxQuant 1.5.1.0 was applied45 and the Perseus module was used46. For label free quantification (LFQ) values of the identified proteins were taken and proteins that were only identified by site or potential contaminants were excluded.
The doxycycline induced (+DOX) and the not induced (−DOX) samples were grouped and at least three valid values in each group were necessary to enter further analysis. The missing values were replaced from normal distribution using the imputation feature of Perseus (width, 0.3; down-shift, 1.8). Subsequently, a gene set enrichment analysis (GSEA) was performed using gsea2-2.2.3 from the Broad Institute (Cambridge, MA, USA)47,48. As underlying gene set database the gene ontology biological process (GO_BP) was used49. The resulting, differentially expressed pathways were grouped in the following categories: metabolism, signalling, migration, cell differentiation, transport, cell development, immune system, gene expression and cell cycle to allow a comparison of up and down regulated signalling cascades.
In order to elucidate the clinical significance of GRK5 and GRPR in breast cancer patients the Kaplan-Meier-Plotter was utilized24 (released 2018/05/01). This web service allows the evaluation of more than 20,000 genes in about 1,800 breast cancer patients. MDA-MB-231 cells represent an example for a triple-negative breast cancer with a basal subtype according to its gene expression profile. Thus, patients with basal like tumours were analysed and the filters were set accordingly. Distant metastasis free survival (DMFS) was chosen as endpoint as cancer cell migration and invasion were of special interest in this study.
Data availability
Data for GSEA are available at https://doi.org/10.6084/m9.figshare.7415633.
References
Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3, 639–650, https://doi.org/10.1038/nrm908 (2002).
Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. Nat Rev Cancer 7, 79–94, https://doi.org/10.1038/nrc2069 (2007).
Siderovski, D. P., Hessel, A., Chung, S., Mak, T. W. & Tyers, M. A new family of regulators of G-protein-coupled receptors? Curr Biol 6, 211–212 (1996).
Premont, R. T., Inglese, J. & Lefkowitz, R. J. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9, 175–182 (1995).
Gurevich, E. V., Tesmer, J. J., Mushegian, A. & Gurevich, V. V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 133, 40–69, https://doi.org/10.1016/j.pharmthera.2011.08.001 (2012).
Komolov, K. E. & Benovic, J. L. G protein-coupled receptor kinases: Past, present and future. Cell Signal 41, 17–24, https://doi.org/10.1016/j.cellsig.2017.07.004 (2018).
Shenoy, S. K. & Lefkowitz, R. J. beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32, 521–533, https://doi.org/10.1016/j.tips.2011.05.002 (2011).
Nogues, L. et al. G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs. Semin Cancer Biol 48, 78–90, https://doi.org/10.1016/j.semcancer.2017.04.013 (2018).
Gambardella, J. et al. Dual role of GRK5 in cancer development and progression. Transl Med UniSa 14, 28–37 (2016).
Yu, S., Sun, L., Jiao, Y. & Lee, L. T. O. The Role of G Protein-coupled Receptor Kinases in Cancer. Int J Biol Sci 14, 189–203, https://doi.org/10.7150/ijbs.22896 (2018).
Kaur, G. et al. G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. J Clin Neurosci 20, 1014–1018, https://doi.org/10.1016/j.jocn.2012.10.008 (2013).
Chakraborty, P. K. et al. G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. Cancer Res 74, 3489–3500, https://doi.org/10.1158/0008-5472.CAN-13-2708 (2014).
Buchholz, M. et al. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. PLoS One 10, e0122946, https://doi.org/10.1371/journal.pone.0122946 (2015).
Jiang, L. P. et al. GRK5 functions as an oncogenic factor in non-small-cell lung cancer. Cell Death Dis 9, 295, https://doi.org/10.1038/s41419-018-0299-1 (2018).
Nogues, L. et al. G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis. EBioMedicine 13, 132–145, https://doi.org/10.1016/j.ebiom.2016.09.030 (2016).
Uhlen, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4, 1920–1932, https://doi.org/10.1074/mcp.M500279-MCP200 (2005).
Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, https://doi.org/10.1126/science.aan2507 (2017).
American Cancer Society. Cancer Facts & Figures 2018, https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html (2018).
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29, 1039–1045, https://doi.org/10.1038/nbt.2017 (2011).
Gao, Y. et al. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J 451, 313–328, https://doi.org/10.1042/BJ20121418 (2013).
Goodman, V. L. et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13, 1367–1373, https://doi.org/10.1158/1078-0432.CCR-06-2328 (2007).
Rock, E. P. et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12, 107–113, https://doi.org/10.1634/theoncologist.12-1-107 (2007).
Polyzos, A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 108, 261–266, https://doi.org/10.1016/j.jsbmb.2007.09.004 (2008).
Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725–731, https://doi.org/10.1007/s10549-009-0674-9 (2010).
Gonzalez, N., Moody, T. W., Igarashi, H., Ito, T. & Jensen, R. T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 15, 58–64, https://doi.org/10.1097/MED.0b013e3282f3709b (2008).
Ramos-Alvarez, I. et al. Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides 72, 128–144, https://doi.org/10.1016/j.peptides.2015.04.026 (2015).
Moreno, P., Ramos-Alvarez, I., Moody, T. W. & Jensen, R. T. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets 20, 1055–1073, https://doi.org/10.1517/14728222.2016.1164694 (2016).
Dalm, S. U. et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med 56, 752–757, https://doi.org/10.2967/jnumed.114.153023 (2015).
Chao, C., Ives, K., Hellmich, H. L., Townsend, C. M. Jr. & Hellmich, M. R. Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression. J Surg Res 156, 26–31, https://doi.org/10.1016/j.jss.2009.03.072 (2009).
Jaeger, N., Czepielewski, R. S., Bagatini, M., Porto, B. N. & Bonorino, C. Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells. Tumour Biol 39, 1010428317694321, https://doi.org/10.1177/1010428317694321 (2017).
Nagakawa, O., Ogasawara, M., Murata, J., Fuse, H. & Saiki, I. Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 8, 65–70 (2001).
Tell, R. et al. Gastrin-releasing peptide signaling alters colon cancer invasiveness via heterochromatin protein 1Hsbeta. Am J Pathol 178, 672–678, https://doi.org/10.1016/j.ajpath.2010.10.017 (2011).
Seifert, S. & Sontheimer, H. Bradykinin enhances invasion of malignant glioma into the brain parenchyma by inducing cells to undergo amoeboid migration. J Physiol 592, 5109–5127, https://doi.org/10.1113/jphysiol.2014.274498 (2014).
Kim, D. et al. Inhibitory Effects of Angiotensin II Receptor Blockade on Human Tenon Fibroblast Migration and Reactive Oxygen Species Production in Cell Culture. Transl Vis Sci Technol 7, 20, https://doi.org/10.1167/tvst.7.2.20 (2018).
Shi, L., Zhou, S. S., Chen, W. B. & Xu, L. Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma. Exp Ther Med 13, 3116–3122, https://doi.org/10.3892/etm.2017.4314 (2017).
Vianello, F., Sambado, L., Goss, A., Fabris, F. & Prandoni, P. Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Med 5, 2886–2898, https://doi.org/10.1002/cam4.857 (2016).
Chinchar, E. et al. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell 6, 12, https://doi.org/10.1186/2045-824X-6-12 (2014).
Andrae, N. et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 48, 1831–1841, https://doi.org/10.1016/j.ejca.2012.01.032 (2012).
Bender, C. & Ullrich, A. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines. Int J Cancer 131, E45–55, https://doi.org/10.1002/ijc.26486 (2012).
Zegers, M. M. & Friedl, P. Rho GTPases in collective cell migration. Small GTPases 5, e28997, https://doi.org/10.4161/sgtp.28997 (2014).
Friedl, P., Wolf, K. & Zegers, M. M. Rho-directed forces in collective migration. Nat Cell Biol 16, 208–210, https://doi.org/10.1038/ncb2923 (2014).
Bray, K. et al. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res 15, R91, https://doi.org/10.1186/bcr3487 (2013).
Tannir, N. M. et al. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer, https://doi.org/10.1016/j.clgc.2017.06.005 (2017).
Stewart, S. A. et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493–501 (2003).
Tyanova, S. et al. Visualization of LC-MS/MS proteomics data in MaxQuant. Proteomics 15, 1453–1456, https://doi.org/10.1002/pmic.201400449 (2015).
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13, 731–740, https://doi.org/10.1038/nmeth.3901 (2016).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545–15550, https://doi.org/10.1073/pnas.0506580102 (2005).
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267–273, https://doi.org/10.1038/ng1180 (2003).
Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25–29, https://doi.org/10.1038/75556 (2000).
Acknowledgements
The authors thank Prof. Axel Ullrich for the initiation of the project, his guidance and great support, Melinda Kiss for support in cell culture work and Miwako Kösters for MS sample preparation. Moreover, the authors thank Axel Ullrich’s Lab for providing cDNA samples of different breast cancer cell lines. The study was funded by the German Research Foundation (DFG), SFB 1032 project B4. A.S. was funded by a doctoral fellowship of the Hanns-Seidel Stiftung.
Author information
Authors and Affiliations
Contributions
Conceptualization, A.R. and A.S.; Methodology: A.S. and A.R.; Data Curation, A.S.; Investigation, A.S.; Writing-Original Draft Preparation, A.S. and A.R.; Writing-Review & Editing, B.L., M.F., T.F., G.J.A. and E.W.; Supervision, A.R., M.F. and E.W., Cell line generation, B.L., Proteomics measurement, T.F. and G.J.A.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sommer, AK., Falcenberg, M., Ljepoja, B. et al. Downregulation of GRK5 hampers the migration of breast cancer cells. Sci Rep 9, 15548 (2019). https://doi.org/10.1038/s41598-019-51923-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-019-51923-1
This article is cited by
-
Computational analysis of G-protein-coupled receptor kinase family members as potential targets for colorectal cancer therapy
Egyptian Journal of Medical Human Genetics (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.